Clinical Trials Logo
NCT number NCT03498261
Study type Interventional
Source Ohio State University
Contact
Status Active, not recruiting
Phase Phase 1
Start date January 30, 2018
Completion date February 7, 2020

Clinical Trial Summary

Adding a single preoperative dose of gabapentin to the standard pain regimen will reduce postoperative opioid consumption within the first 72 hours in patients undergoing rhinoplasty.


Clinical Trial Description

Study Design A prospective randomized double blind study will be conducted to assess the effect of a single preoperative dose of gabapentin on postoperative opioid consumption within the first 72 hours when compared to oral placebo in patients undergoing rhinoplasty at The Ohio State University Wexner Medical Center.

Preoperative Period After assessing patients' eligibility on the day of the surgery and written informed consent is obtained, subjects will be randomized into two groups: placebo group (group I) and gabapentin group (group II).

Pain level will be assessed and recorded at baseline using the verbal NPRS. A single dose of study medication will be administered within 2 hours before scheduled surgery time. Patients randomized to group I will receive matched oral placebo whereas patients randomized to group II will receive 900 mg of oral gabapentin. Once provided by pharmacy, the study medication will be administered by a blinded nurse in the preoperative area.

Intraoperative Period General anesthesia with desflurane and fentanyl will be provided in all patients. Other anesthetic procedures including intraoperative monitoring, muscle relaxation, endotracheal intubation, mechanical ventilation, fluid management, and the use of intravenous dexamethasone will be carried out in accordance with standard procedures. Ondansetron (4 mg) will be used as PONV prophylaxis in all patients 30 minutes before the end of the surgery. Moreover, an orogastric tube (OGT) will be used for stomach emptying at the end of the surgery and before the emergence of anesthesia.

Postoperative period Closure time will be recorded as T0. The time elapsed from PACU arrival until the first opioid dose (either oral or IV) will be recorded. Once in PACU, patients will receive IV fentanyl as pain rescue medication if required and PACU length of stay will be also recorded. After patients are considered stable based on clinician assessment and willingness to start oral intake, a treatment with oral acetaminophen 650 mg scheduled every 6 hours and oral oxycodone (5-10 mg) as needed (PRN) will be initiated for all patients.

Anesthesiologists and researchers evaluating postoperative outcomes will be blinded. The verbal NPRS will be used to assess postoperative pain level at PACU arrival, and every 30 minutes until hospital discharge. After discharge, pain levels will be recorded by patients in their diary at T6, T12, T24 (6, 12, and 24 hours after T0 respectively), and before requiring breakthrough medication (oxycodone) until postoperative day (POD) 7.

Follow-up phase Patients will be discharged home as per standard of care with oral acetaminophen 650 mg scheduled every 6 hours and a prescription for oral oxycodone 5-10 mg every 4 hours as needed (PRN). At discharge, the patient will be instructed to record his oral opioid consumption (oxycodone) and NPRS scores before each oxycodone dose until POD 7 (see attached diary).

A follow-up visit will be matched with the standard postsurgical visit at POD 7 in order to collect the diary, and count the remaining pills from the oxycodone bottle. Adverse events (AEs) including nausea and vomiting will be assessed and documented during the whole study participation.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Not yet recruiting NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Not yet recruiting NCT03230565 - Continuous Infusions vs Scheduled Bolus Infusions N/A
Recruiting NCT03245359 - Pain Management After TKA: Comparison of Short- and Long-term Nerve Blocks N/A
Active, not recruiting NCT03302689 - Comparison Levobupivacaine and Ropivacaine for TAP-block After Caesarean Section N/A
Recruiting NCT03502369 - Ultrasound Guided Quadratus Lumborum Block for Post Operative Analgesia After Hip Arthroplasty N/A
Withdrawn NCT03137030 - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults Phase 1
Withdrawn NCT03137017 - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults Phase 1
Recruiting NCT02949674 - Ropivacaine Versus Bupivacaine as Preemptive Analgesia in Surgical Site in Ankle Fracture Patients Phase 3
Completed NCT03478241 - Postoperative Pain Intensity Associated With the Use of Different Nickel Titanium Instrumentation Systems N/A
Completed NCT02738710 - Comparison of Post-operative Pain at Umbilical Wound After Laparoscopic Cholecystectomy With Transumbilical Versus Infraumbilical Incision N/A
Active, not recruiting NCT02579538 - Flexibility of Cognition And Persistent Pain N/A
Not yet recruiting NCT01329120 - Short and Long-term Effects of Surgical Repair of Pectus Deformities N/A
Recruiting NCT02216305 - HAL-RAR Versus Hemorrhoidectomy in the Treatment of Grade III-IV Hemorrhoids. Prospective, Randomized Trial Phase 4
Completed NCT02302586 - Thoracic Paravertebral Blockade in Video Assisted Thoracoscopic Surgery (VATS) Phase 4
Recruiting NCT02456116 - Efficiency Study About the Effect of Acupuncture on Postoperative Pain After Total Knee Arthroplasty N/A
Unknown status NCT01688596 - Injection of Local Anesthetic to Trocar Insertion Sites After Laparoscopy Phase 1
Completed NCT01692392 - Health-related Quality of Life in Patients Undergoing Surgery for Pectus Carinatum N/A
Terminated NCT01430182 - Intraoperative Methadone vs Morphine for Postoperative Pain Control in Patients Undergoing Surgery of the Tibia N/A
Recruiting NCT01230463 - Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose. N/A